Brady Bernard
0000-0003-2118-9829
Publication & Citation Trends
Publications
0 total
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing OA
Cited by 27
Semantic Scholar
Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Cited by 0
Semantic Scholar
Abstract 3399: Tumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapies
Cited by 0
Semantic Scholar
Abstract 6764: Multi-parametric comparison of scRNA-seq with CITE-seq and ultrahigh-plex spatial phenotyping of proteins in FFPE head and neck tumor biopsies: An opportunity to generate uniquely comprehensive multi-omic single cell datasets to investigate the tumor microenvironment
Cited by 1
Semantic Scholar
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer OA
Cited by 5
Semantic Scholar
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. OA
Cited by 109
Semantic Scholar
PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors OA
Cited by 46
Semantic Scholar
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer OA
Cited by 16
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(58)
Cancer Immunotherapy and Biomarkers
(42)
Immunotherapy and Immune Responses
(19)
Natural Language Processing Techniques
(16)
Lung Cancer Treatments and Mutations
(14)
Affiliations
BC Cancer Agency
National Institutes of Health
Oregon Research Institute
The University of Texas MD Anderson Cancer Center
Oregon Health & Science University